Longevity Roundtable: GLP-1s, Statins, Aging Clocks & Right to Try

Longevity research and clinical interventions remain at the forefront of scientific inquiry, with recent findings challenging conventional wisdom on metabolic and cognitive health. Intermittent Hypoxic Hyperoxic Therapy (IHHT) offers a promising mechanism for physiological adaptation, while the efficacy of hyperbaric oxygen therapy (HBOT) in healthy individuals requires more robust clinical validation. GLP-1 agonists, while effective for metabolic regulation and lifespan extension in preclinical models, warrant cautious application in healthy populations due to unknown long-term effects. Furthermore, evidence suggests statins may protect against dementia, countering concerns that lipid-lowering drugs negatively impact brain health. Epigenetic clocks serve as valuable tools for tracking biological age, though they often conflate general health status with aging, complicating the assessment of specific interventions. Meanwhile, new regulatory frameworks like Montana’s "Right to Try" laws aim to provide safer, more transparent access to experimental therapies.